PMID- 37499274
OWN - NLM
STAT- MEDLINE
DCOM- 20230804
LR  - 20230804
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 37
IP  - 8
DP  - 2023 Aug
TI  - Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in 
      non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An 
      updated meta-analysis of randomized controlled trials.
PG  - 108558
LID - S1056-8727(23)00156-3 [pii]
LID - 10.1016/j.jdiacomp.2023.108558 [doi]
AB  - BACKGROUND AND AIM: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has been 
      verified to improve Non-alcoholic fatty liver disease (NAFLD) in previous 
      clinical practice. We mainly aim to investigate the effects of SGLT2i on liver 
      fibrosis in NAFLD patients with type 2 diabetes mellitus (T2DM). METHODS: We 
      conducted a comprehensive literature search utilizing the databases PubMed, 
      Embase, Web of Science, and Cochrane Library, and extracted continuous data in 
      the form of mean and standard deviation of the difference before and after 
      treatment. RevMan 5.3 software was used to chart the pooled forest plot and 
      perform heterogeneity, sensitivity and subgroup analysis. This study is conducted 
      under the protocol registered with the Platform of Registered Systematic Review 
      and Meta-analysis Protocols (INPLASY protocol 4946, INPLASY202360058). RESULTS: A 
      total of 16 articles involving 699 patients were included. Indicators of liver 
      fibrosis, containing Liver Stiffness Measurement (LSM), Controlled Attenuation 
      Parameter (CAP), Serum ferritin, Serum type 4 collagen 7s, and FIB-4 index, were 
      found to be considerably reduced by SGLT2i medication and subgroup analysis 
      manifested pronounced dose-dependence. Additionally, SGLT2i therapy decreased 
      BMI, lipid buildup and insulin resistance. CONCLUSIONS: SGLT2 inhibitors 
      significantly ameliorated liver fibrosis and liver fat content, improved body 
      conditions and insulin resistance, demonstrating that SGLT2i might reduce the 
      risk of the progression of liver fibrosis and have a positive effect on NAFLD 
      patients with T2DM.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Jin, Zijie
AU  - Jin Z
AD  - Fudan University School of Pharmacy, Shanghai 201203, China. Electronic address: 
      zijiejin21@m.fudan.edu.cn.
FAU - Yuan, Yan
AU  - Yuan Y
AD  - Fudan University School of Pharmacy, Shanghai 201203, China.
FAU - Zheng, Chen
AU  - Zheng C
AD  - Fudan University School of Pharmacy, Shanghai 201203, China.
FAU - Liu, Shijian
AU  - Liu S
AD  - Department of Clinical Epidemiology and Biostatistics, Child Health Advocacy 
      Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao 
      Tong University, Shanghai 200127, China. Electronic address: 
      liushijian@scmc.com.cn.
FAU - Weng, Hongbo
AU  - Weng H
AD  - Fudan University School of Pharmacy, Shanghai 201203, China. Electronic address: 
      hbweng@fudan.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20230719
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Insulin Resistance
MH  - Liver Cirrhosis/complications/drug therapy
MH  - *Non-alcoholic Fatty Liver Disease/complications/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Liver fibrosis
OT  - NAFLD
OT  - NASH
OT  - SGLT2 inhibitors
OT  - T2DM
COIS- Declaration of competing interest This study declares no conflict of interest.
EDAT- 2023/07/27 19:10
MHDA- 2023/08/04 06:43
CRDT- 2023/07/27 18:00
PHST- 2023/05/07 00:00 [received]
PHST- 2023/06/25 00:00 [revised]
PHST- 2023/07/11 00:00 [accepted]
PHST- 2023/08/04 06:43 [medline]
PHST- 2023/07/27 19:10 [pubmed]
PHST- 2023/07/27 18:00 [entrez]
AID - S1056-8727(23)00156-3 [pii]
AID - 10.1016/j.jdiacomp.2023.108558 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2023 Aug;37(8):108558. doi: 
      10.1016/j.jdiacomp.2023.108558. Epub 2023 Jul 19.